Reviewing BioSpecifics Technologies Corp. (BSTC)’s and AVEO Pharmaceuticals Inc. (NASDAQ:AVEO)’s results

BioSpecifics Technologies Corp. (NASDAQ:BSTC) and AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioSpecifics Technologies Corp. 29.81M 16.52 16.51M 2.40 29.63
AVEO Pharmaceuticals Inc. 4.01M 20.62 23.65M -0.20 0.00

Table 1 highlights BioSpecifics Technologies Corp. and AVEO Pharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 provides us BioSpecifics Technologies Corp. and AVEO Pharmaceuticals Inc.?s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
BioSpecifics Technologies Corp. 55.38% 21.8% 20.7%
AVEO Pharmaceuticals Inc. -589.78% 48.1% -69.9%

Volatility and Risk

BioSpecifics Technologies Corp. has a 1.29 beta, while its volatility is 29.00%, thus making it more volatile than Standard and Poor’s 500. AVEO Pharmaceuticals Inc. on the other hand, has 1.13 beta which makes it 13.00% more volatile compared to Standard and Poor’s 500.


48.4 and 48.4 are the respective Current Ratio and a Quick Ratio of BioSpecifics Technologies Corp. Its rival AVEO Pharmaceuticals Inc.?s Current and Quick Ratios are 1.1 and 1.1 respectively. BioSpecifics Technologies Corp. has a better chance of clearing its pay short and long-term debts than AVEO Pharmaceuticals Inc.

Analyst Ratings

Recommendations and Ratings for BioSpecifics Technologies Corp. and AVEO Pharmaceuticals Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
BioSpecifics Technologies Corp. 0 0 0 0.00
AVEO Pharmaceuticals Inc. 0 2 2 2.50

AVEO Pharmaceuticals Inc. on the other hand boasts of a $2 average target price and a 288.65% potential upside.

Institutional & Insider Ownership

Institutional investors held 61.3% of BioSpecifics Technologies Corp. shares and 41.9% of AVEO Pharmaceuticals Inc. shares. Insiders held roughly 2.5% of BioSpecifics Technologies Corp.’s shares. Competitively, AVEO Pharmaceuticals Inc. has 0.3% of it’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
BioSpecifics Technologies Corp. 2.61% 9.45% 20.32% 40.89% 78.69% 17.36%
AVEO Pharmaceuticals Inc. -15.19% -19.85% -72.92% -80.67% -80.4% -64.96%

For the past year BioSpecifics Technologies Corp. had bullish trend while AVEO Pharmaceuticals Inc. had bearish trend.


BioSpecifics Technologies Corp. beats AVEO Pharmaceuticals Inc. on 9 of the 12 factors.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of Dupuytren’s contracture and Peyronie’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company’s pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent’s Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.